Optimization of Saturation Targets And Resuscitation Trial (OptiSTART)

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age0-10
SponsorUniversity of Texas Southwestern Medical Center

About this trial

This study is designed to answer one of the fundamental gaps in knowledge in the resuscitation of preterm infants at birth: What is the optimal target oxygen saturation (SpO2) range that increases survival without long-term morbidities? Oxygen (O2) is routinely used for the stabilization of preterm infants in the delivery room (DR), but its use is linked with mortality and several morbidities including bronchopulmonary dysplasia (BPD). To balance the need to give sufficient O2 to correct hypoxia and avoid excess O2, the neonatal resuscitation program (NRP) recommends initiating preterm resuscitation with low (≤ 30%) inspired O2 concentration (FiO2) and subsequent titration to achieve a specified target SpO2 range. These SpO2 targets are based on approximated 50th percentile SpO2 (Sat50) observed in healthy term infants. However, the optimal SpO2 targets remain undefined in the preterm infants. Recent data suggest that the current SpO2 targets (Sat50) may be too low. The investigators plan to conduct a multicenter RCT of Sat75 versus Sat50 powered for survival without BPD. The investigators will randomize 700 infants, 23 0/7- 30 6/7 weeks' GA, to 75th percentile SpO2 goals (Sat75, Intervention) or 50th percentile SpO2 goals (Sat50, control). Except for the SpO2 targets, all resuscitations will follow NRP guidelines including an initial FiO2 of 0.3. In Aim 1, the investigators will determine whether targeting Sat75 compared to Sat50 increases survival without lung disease (BPD). In addition, the investigators will compare the rates of other major morbidities such as IVH. In Aim 2, the investigators will determine whether targeting Sat75 compared to Sat50 increases survival without neurodevelopmental impairment at 2 years of age. In Aim 3, the investigators will determine whether targeting Sat75 compared to Sat50 decreases oxidative stress.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

Prenatally diagnosed cyanotic congenital heart disease

Prenatally diagnosed congenital diaphragmatic hernia

Parents request no resuscitation

If preductal saturations can not be measured by 3 minutes after pulse oximeter sensor is applied to the newborn

Trial design

Design model

Parallel

Treatments tested in this trial

  • Sat75

    Other intervention

    As per the current NRP guidelines, resuscitation will be initiated with 0.3 FiO2. FiO2 will be titrated every 30 seconds by 0.2-0.3 to achieve target SpO2 that approximates the 75th percentile SpO2 observed in healthy term newborns. Percentiles are roughly based on Dawson reference curves of healthy term infants after birth. Apart from the randomly assigned target SpO2, resuscitation will follow the current NRP guidelines. Following NICU admission, all care decisions, including ventilator management, will be at the discretion of the clinical team.

  • Sat50

    Other intervention

    As per the current NRP guidelines, resuscitation will be initiated with 0.3 FiO2. FiO2 will be titrated every 30 seconds by 0.1-0.2 to achieve target SpO2 that approximates the 50th percentile SpO2 observed in healthy term newborns. Percentiles are roughly based on Dawson reference curves of healthy term infants after birth. Apart from the randomly assigned target SpO2, resuscitation will follow the current NRP guidelines. Following NICU admission, all care decisions, including ventilator management, will be at the discretion of the clinical team.

Treatment groups

700 Participants
are divided into 2 treatment groups
Group A: Sat75Experimental treatment 1 intervention
Group B: Sat50Active comparator 1 intervention

Trial outcomes

Primary outcomes

1

Survival without BPD

The primary outcome for this trial is survival without BPD at 36 weeks' PMA. Both components, death and BPD, will also be reported separately. Neonatal mortality during the NICU stay, the postnatal day at the time of mortality and the primary cause of mortality will be recorded. BPD will be defined as the need for any form of positive airway pressure support or supplemental O2 at 36 weeks' PMA.BPD will be graded as mild, moderate and severe as per the NICHD consensus definition. All eligible infants will undergo room air challenge at 36 weeks' PMA for the physiologic definition of BPD.

Time frame
36 weeks Postmenstrual Age

Secondary outcomes

1

Bronchopulmonary Dysplasia

BPD will be defined as the need for any form of positive airway pressure support or supplemental O2 at 36 weeks' PMA.BPD will be graded as mild, moderate and severe as per the NICHD consensus definition. All eligible infants will undergo room air challenge at 36 weeks' PMA for the physiologic definition of BPD. In addition, BPD by Jensen Criteria will also be used as a secondary outcome. Respiratory support at 40 weeks PMA and at discharge will also be collected

Time frame
36 weeks PMA, 40 weeks PMA and at Discharge
2

Oxygen saturations in the delivery room

High resolution SpO2 data with 2 second frequency from pulse oximeter will be collected. Average Spo2 value every 30 seconds will be plotted. The investigators will also calculate time spent in the desired target, above the target or below the target.

Time frame
First 15 minutes after birth
3

SpO2<80% at 5 minutes after birth

SpO2\<80% at 5 minutes after birth

Time frame
First 5 minutes after birth
4

Delivery Room Intubation

The investigators will record if the newborn was intubated in the delivery room

Time frame
Up to first 30 minutes after birth

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Texas Southwestern Medical Center

Lead sponsor

University of Alabama at Birmingham

Collaborator

University of Oklahoma

Collaborator

North Central Baptist Hospital

Collaborator

Sharp Mary Birch Hospital for Women & Newborns

Collaborator

The Woman's Hospital of Texas

Collaborator

Baylor College of Medicine

Collaborator

University of Florida Health

Collaborator

University of Pittsburgh Medical Center

Collaborator

University of Pittsburgh

Collaborator

University of Utah

Collaborator

Primary Children's Hospital

Collaborator

Methodist Children's Hospital

Collaborator